Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study

Background Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. Aim The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on sympt...

Full description

Saved in:
Bibliographic Details
Published inDigestive diseases and sciences Vol. 60; no. 1; pp. 186 - 194
Main Authors Wong, Reuben K., Yang, Cao, Song, Guang-Hui, Wong, Jennie, Ho, Khek-Yu
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.01.2015
Springer
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0163-2116
1573-2568
1573-2568
DOI10.1007/s10620-014-3299-8

Cover

Abstract Background Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. Aim The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels. Methods Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays. Results Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores ( r  = 0.51, p  = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated ( r  = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits ( r  = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life. Conclusions VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.
AbstractList Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels. Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays. Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores (r = 0.51, p = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated (r = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits (r = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life. VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.
Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels. Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays. Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores (r = 0.51, p = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated (r = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits (r = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life. VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.[PUBLICATION ABSTRACT]
Background Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. Aim The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels. Methods Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays. Results Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores (r = 0.51, p = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated (r = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits (r = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life. Conclusions VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.
Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels. Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays. Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores (r = 0.51, p = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated (r = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits (r = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life. VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.
Background Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms. Aim The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels. Methods Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays. Results Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores ( r  = 0.51, p  = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated ( r  = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits ( r  = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life. Conclusions VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.
Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms.BACKGROUNDProbiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin levels, leading to changes in IBS symptoms.The purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels.AIMThe purpose of this study was to evaluate the effects of a probiotic, VSL#3, on symptoms, psychological and sleep parameters, and pain sensitivity in IBS, and relate these parameters to in vivo melatonin levels.Forty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays.METHODSForty-two IBS patients were randomly assigned to receive VSL#3 or placebo for 6 weeks. Subjects completed bowel and psychological questionnaires, underwent rectal sensitivity testing and saliva melatonin assays.Abdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores (r = 0.51, p = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated (r = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits (r = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life.RESULTSAbdominal pain duration and distension intensity decreased significantly in the probiotic group, along with an increase in rectal distension pain thresholds. A correlation between increase in pain tolerance and improvement in abdominal pain scores (r = 0.51, p = 0.02) was seen with probiotic. There was an increase in salivary morning melatonin levels in males treated with VSL#3, which correlated (r = 0.61) with improved satisfaction in bowel habits. When grouped based on baseline diurnal melatonin levels, patients with normal diurnal fluctuations showed an increase in morning melatonin levels with VSL#3 treatment, which significantly correlated with improved satisfaction in bowel habits (r = 0.68). They also had reduced symptom severity scores and abdominal pain duration when treated with VSL#3, as well as satisfaction with bowel movements and quality-of-life.VSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.CONCLUSIONSVSL#3 improved symptoms and increased rectal pain thresholds. Symptom improvement correlated with a rise in morning melatonin, significant in males and subjects with normal circadian rhythm. This suggests that probiotics may act by influencing melatonin production, hence modulating IBS symptoms, in individuals with a normal circadian rhythm.
Audience Professional
Academic
Author Wong, Jennie
Wong, Reuben K.
Yang, Cao
Song, Guang-Hui
Ho, Khek-Yu
Author_xml – sequence: 1
  givenname: Reuben K.
  surname: Wong
  fullname: Wong, Reuben K.
  email: reuben_wong@nuhs.edu.sg
  organization: Department of Gastroenterology and Hepatology, National University Health System
– sequence: 2
  givenname: Cao
  surname: Yang
  fullname: Yang, Cao
  organization: Department of Medicine, Yong Loo Lin School of Medicine
– sequence: 3
  givenname: Guang-Hui
  surname: Song
  fullname: Song, Guang-Hui
  organization: Department of Medicine, Yong Loo Lin School of Medicine
– sequence: 4
  givenname: Jennie
  surname: Wong
  fullname: Wong, Jennie
  organization: Department of Medicine, Yong Loo Lin School of Medicine
– sequence: 5
  givenname: Khek-Yu
  surname: Ho
  fullname: Ho, Khek-Yu
  organization: Department of Gastroenterology and Hepatology, National University Health System, Department of Medicine, Yong Loo Lin School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25092036$$D View this record in MEDLINE/PubMed
BookMark eNqNkt9uFCEUxompsdvqA3hjSHpTL6YCMwMz3m1r1SbbuOmqt4SFw0ozAxVmYrZv4FvLZNuojRrDBX_y-74DnO8A7fngAaHnlJxQQsSrRAlnpCC0KkrWtkXzCM1oLcqC1bzZQzNCeV5TyvfRQUrXhJBWUP4E7bOatIyUfIa-X0KnhuCdx1ewGfPaBY9VwgovQ0pu3QG-BP1FeZd6bEPEyxjWLgxO4-PPq8VR-RJn7UWMblATfBq-QYdXW29i6OE1nuMr5U3o3S0Y_CaMmSlOO-dN3i47pWEd8GoYzfYpemxVl-DZ3XyIPr09_3j2vlh8eHdxNl8Uuq7YUAhmqAYQtrFGmKatjGhpxY2GmjScWGosB94aq6iAljY1Y0yVlq1bA3UtaHmIjne-NzF8HSENsndJQ9cpD2FMkvK64pyXzf-gVZlrlw3P6NED9DqM0eeHTBSjZUOq5ie1UR1I520YotKTqZwLytqqopRk6uQPVB4GeqdzBKzL578JXtwVH9c9GHkTXa_iVt63OQNiB-iYmxrBSp3bNbU6O7tOUiKnQMldoGQOlJwCJacb0wfKe_N_adhOkzLrNxB_-Yu_in4AVuDZPg
CODEN DDSCDJ
CitedBy_id crossref_primary_10_3389_fphar_2022_853011
crossref_primary_10_1038_s41430_020_0656_x
crossref_primary_10_3390_jcm10163497
crossref_primary_10_3390_medicina59101731
crossref_primary_10_1016_j_jnutbio_2018_04_004
crossref_primary_10_1007_s00535_016_1224_y
crossref_primary_10_1111_nmo_14751
crossref_primary_10_12998_wjcc_v8_i8_1361
crossref_primary_10_1515_bmc_2017_0009
crossref_primary_10_1016_j_jfma_2022_10_001
crossref_primary_10_3390_nu11092048
crossref_primary_10_3389_fpain_2021_691689
crossref_primary_10_3390_nu10111723
crossref_primary_10_1007_s40474_018_0147_0
crossref_primary_10_3389_fmicb_2016_01934
crossref_primary_10_3390_nu15173856
crossref_primary_10_1111_jam_13594
crossref_primary_10_4103_epj_epj_66_21
crossref_primary_10_1186_s12876_016_0470_z
crossref_primary_10_1007_s11938_023_00433_1
crossref_primary_10_1007_s00210_024_02972_5
crossref_primary_10_1517_17460441_2015_1049528
crossref_primary_10_4240_wjgs_v13_i9_923
crossref_primary_10_1007_s12088_022_01019_8
crossref_primary_10_29413_ABS_2024_9_2_2
crossref_primary_10_1016_j_phanu_2019_100164
crossref_primary_10_1111_nmo_13473
crossref_primary_10_3390_ijms150915858
crossref_primary_10_3390_nu9101124
crossref_primary_10_1038_s41522_024_00605_6
crossref_primary_10_1097_MCG_0000000000002002
crossref_primary_10_1016_j_jff_2018_05_051
crossref_primary_10_1080_00325481_2017_1383819
crossref_primary_10_1111_nmo_13427
crossref_primary_10_1007_s11894_017_0601_x
crossref_primary_10_1093_nutrit_nuad027
crossref_primary_10_3390_ijms21239255
crossref_primary_10_1017_S0007114521000568
crossref_primary_10_1097_JS9_0000000000000658
crossref_primary_10_4274_jtsm_galenos_2023_97658
crossref_primary_10_1186_s41043_024_00601_8
crossref_primary_10_3389_fmicb_2019_00740
crossref_primary_10_1016_j_jsams_2020_08_005
crossref_primary_10_3748_wjg_v24_i38_4297
crossref_primary_10_1089_jmf_2023_0062
crossref_primary_10_1007_s11684_018_0645_9
crossref_primary_10_1038_s41395_018_0084_x
crossref_primary_10_3390_jof8040365
crossref_primary_10_3390_antiox11112244
crossref_primary_10_18632_oncotarget_21504
crossref_primary_10_3390_microorganisms7020041
crossref_primary_10_1016_j_tifs_2023_06_013
crossref_primary_10_1093_jcag_gwy071
crossref_primary_10_1111_jcpt_12749
crossref_primary_10_3390_nu15030550
crossref_primary_10_1002_brb3_1408
crossref_primary_10_1111_apt_15001
crossref_primary_10_1016_j_mehy_2015_10_030
crossref_primary_10_3390_nu14163271
crossref_primary_10_3389_fcimb_2022_859967
crossref_primary_10_3390_ph16030357
crossref_primary_10_3390_microbiolres12030043
crossref_primary_10_1016_j_brainresbull_2021_12_016
crossref_primary_10_1016_j_foodres_2020_109437
crossref_primary_10_1021_acschemneuro_3c00127
crossref_primary_10_1016_j_tifs_2021_01_007
crossref_primary_10_9778_cmajo_20200283
crossref_primary_10_1016_j_gtc_2021_03_009
crossref_primary_10_3746_pnf_2024_29_3_237
crossref_primary_10_1016_j_cbpb_2021_110634
crossref_primary_10_1038_s41598_024_53810_w
crossref_primary_10_1097_MCG_0000000000000963
crossref_primary_10_4103_sjg_SJG_384_19
crossref_primary_10_1016_j_biopha_2020_110496
crossref_primary_10_3390_clockssleep5040050
Cites_doi 10.1016/0165-1781(89)90047-4
10.1111/j.1572-0241.2005.40312.x
10.1080/00365520310002166
10.1136/gut.2003.028514
10.1016/j.ejpain.2008.09.015
10.1111/j.1365-2036.1996.tb00181.x
10.1159/000127186
10.1016/j.pain.2006.06.017
10.1016/S0140-6736(98)02146-1
10.1080/00365520410007953
10.1097/00005176-199610000-00013
10.2174/1568026023394335
10.1046/j.1365-2036.1997.142318000.x
10.1111/j.1365-2036.2005.02673.x
10.7326/0003-4819-111-8-671
10.1080/15287398809531139
10.1016/j.femsim.2004.08.009
10.1023/A:1020107915919
10.1136/bmj.310.6973.171
10.1053/j.gastro.2004.03.024
10.1111/j.1600-0447.1983.tb09716.x
10.1111/j.1365-2982.2005.00695.x
10.1016/j.pain.2009.10.005
10.1007/BF03343838
10.1111/j.1365-2982.2010.01520.x
10.1136/gut.2004.062034
10.1016/S1471-4892(02)00224-2
10.1177/0748730410374943
10.1097/AJP.0b013e3181bff800
10.1053/j.gastro.2004.11.050
10.3748/wjg.v13.i27.3699
10.1111/j.1572-0241.2004.04161.x
ContentType Journal Article
Copyright Springer Science+Business Media New York 2014
COPYRIGHT 2015 Springer
Springer Science+Business Media New York 2015
Copyright_xml – notice: Springer Science+Business Media New York 2014
– notice: COPYRIGHT 2015 Springer
– notice: Springer Science+Business Media New York 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
FYUFA
GHDGH
K9-
K9.
KB0
M0R
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
7QL
7T7
8FD
C1K
FR3
P64
DOI 10.1007/s10620-014-3299-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Consumer Health Database
ProQuest Health & Medical Collection
Medical Database
Nursing & Allied Health Premium
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
Engineering Research Database
Technology Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Bacteriology Abstracts (Microbiology B)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList MEDLINE
ProQuest One Academic Middle East (New)

Engineering Research Database


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1573-2568
EndPage 194
ExternalDocumentID 3545918081
A712944110
25092036
10_1007_s10620_014_3299_8
Genre Randomized Controlled Trial
Journal Article
Feature
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
-~X
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
354
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8UJ
95-
95.
95~
96X
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AAKAS
AANXM
AANZL
AAQQT
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACREN
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZCM
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BKNYI
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IH2
IHE
IHR
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
J5H
JBSCW
JCJTX
JZLTJ
K9-
KDC
KOV
KOW
KPH
L7B
LAK
LLZTM
M0R
M1P
M4Y
MA-
MJL
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OHH
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RRX
RSV
RXW
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJN
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TAE
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
VVN
W23
W48
WH7
WJK
WK8
WOW
X7M
XOL
YLTOR
YOC
Z45
Z7U
Z7V
Z7W
Z7X
Z81
Z82
Z83
Z87
Z88
Z8O
Z8P
Z8Q
Z8R
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
ZY1
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
AEIIB
PMFND
7XB
8FK
ABRTQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
PUEGO
7QL
7T7
8FD
C1K
FR3
P64
ID FETCH-LOGICAL-c542t-72d1cee7f8fd7d894d79146dce50860f1df6e69dfa17e9185222a3f2b9de55713
IEDL.DBID U2A
ISSN 0163-2116
1573-2568
IngestDate Fri Sep 05 09:53:58 EDT 2025
Fri Sep 05 05:02:14 EDT 2025
Fri Jul 25 05:16:02 EDT 2025
Tue Jun 17 21:30:33 EDT 2025
Tue Jun 10 20:50:52 EDT 2025
Thu Apr 03 07:02:43 EDT 2025
Tue Jul 01 03:44:46 EDT 2025
Thu Apr 24 23:07:30 EDT 2025
Fri Feb 21 02:34:04 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Probiotic
Rectal distension
Melatonin
Circadian rhythm
Irritable bowel syndrome
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c542t-72d1cee7f8fd7d894d79146dce50860f1df6e69dfa17e9185222a3f2b9de55713
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 25092036
PQID 1642138048
PQPubID 41056
PageCount 9
ParticipantIDs proquest_miscellaneous_1654666381
proquest_miscellaneous_1643146386
proquest_journals_1642138048
gale_infotracmisc_A712944110
gale_infotracacademiconefile_A712944110
pubmed_primary_25092036
crossref_citationtrail_10_1007_s10620_014_3299_8
crossref_primary_10_1007_s10620_014_3299_8
springer_journals_10_1007_s10620_014_3299_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-01-01
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – month: 01
  year: 2015
  text: 2015-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Boston
PublicationPlace_xml – name: Boston
– name: United States
– name: New York
PublicationTitle Digestive diseases and sciences
PublicationTitleAbbrev Dig Dis Sci
PublicationTitleAlternate Dig Dis Sci
PublicationYear 2015
Publisher Springer US
Springer
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer
– name: Springer Nature B.V
References Wilder-Smith, Song, Yeoh, Ho (CR30) 2009; 13
Zigmond, Snaith (CR20) 1983; 67
Matto, Maunuksela, Kajander (CR3) 2005; 43
Wilder-Smith, Robert-Yap (CR27) 2007; 13
Lu, Gwee, Moochhalla, Ho (CR15) 2005; 22
Kim, Vazquez Roque, Camilleri (CR5) 2005; 17
Bubenik (CR16) 2002; 47
Sartor (CR10) 2004; 126
Treem, Ahsan, Kastoff, Hyams (CR8) 1996; 23
Wilder-Smith, Schindler, Lovblad, Redmond, Nirkko (CR26) 2004; 53
O’Mahony, McCarthy, Kelly (CR6) 2005; 128
Malinen, Rinttila, Kajander (CR4) 2005; 100
King, Elia, Hunter (CR7) 1998; 352
Guerrero, Reiter (CR31) 2002; 2
Piche, Arsenault, Poitras, Rainville, Bouin (CR29) 2010; 148
Camilleri (CR21) 2002; 2
Houghton, Heyman, Whorwell (CR33) 1996; 10
Song, Leng, Gwee, Moochhala, Ho (CR14) 2005; 54
Radwan, Skrzydlo-Radomanska, Radwan-Kwiatek, Burak-Czapiuk, Strzemecka (CR34) 2009; 60
CR2
McKernan, Fitzgerald, Dinan, Cryan (CR25) 2010; 22
Francis, Morris, Whorwell (CR23) 1997; 11
Song, Venkatraman, Ho, Chee, Yeoh, Wilder-Smith (CR22) 2006; 126
Patacchioli, Angelucci, Dellerba, Monnazzi, Leri (CR12) 2001; 24
Buysse, Reynolds, Monk, Berman, Kupfer (CR19) 1989; 28
Heymen, Maixner, Whitehead, Klatzkin, Mechlin, Light (CR28) 2010; 26
Kellner, Yassouridis, Manz, Steiger, Holsboer, Wiedemann (CR13) 1997; 65
Weinryb, Osterberg, Blomquist, Hultcrantz, Krakau, Asberg (CR11) 2003; 38
Drossman, Dumitrascu (CR17) 2006; 15
Cain, Dennison, Zeitzer (CR35) 2010; 25
Farthing (CR1) 1995; 310
Talley, Phillips, Melton, Wiltgen, Zinsmeister (CR18) 1989; 111
Lamine, Eutamene, Fioramonti, Bueno, Theodorou (CR9) 2004; 39
Hirano, Ono, Aimoto (CR24) 1988; 24
Klupinska, Wisniewska-Jarosinska, Harasiuk (CR32) 2006; 57
M Camilleri (3299_CR21) 2002; 2
G Klupinska (3299_CR32) 2006; 57
3299_CR2
CH Wilder-Smith (3299_CR30) 2009; 13
MJ Farthing (3299_CR1) 1995; 310
LA Houghton (3299_CR33) 1996; 10
WZ Lu (3299_CR15) 2005; 22
GH Song (3299_CR22) 2006; 126
J Matto (3299_CR3) 2005; 43
E Malinen (3299_CR4) 2005; 100
RB Sartor (3299_CR10) 2004; 126
WR Treem (3299_CR8) 1996; 23
RM Weinryb (3299_CR11) 2003; 38
AS Zigmond (3299_CR20) 1983; 67
GA Bubenik (3299_CR16) 2002; 47
CH Wilder-Smith (3299_CR27) 2007; 13
DJ Buysse (3299_CR19) 1989; 28
M Piche (3299_CR29) 2010; 148
F Lamine (3299_CR9) 2004; 39
M Kellner (3299_CR13) 1997; 65
GH Song (3299_CR14) 2005; 54
DA Drossman (3299_CR17) 2006; 15
P Radwan (3299_CR34) 2009; 60
SW Cain (3299_CR35) 2010; 25
HJ Kim (3299_CR5) 2005; 17
NJ Talley (3299_CR18) 1989; 111
FR Patacchioli (3299_CR12) 2001; 24
L O’Mahony (3299_CR6) 2005; 128
CH Wilder-Smith (3299_CR26) 2004; 53
DP McKernan (3299_CR25) 2010; 22
S Hirano (3299_CR24) 1988; 24
TS King (3299_CR7) 1998; 352
S Heymen (3299_CR28) 2010; 26
JM Guerrero (3299_CR31) 2002; 2
CY Francis (3299_CR23) 1997; 11
28443770 - Scand J Gastroenterol. 2003;38(5):503-510
17218759 - J Physiol Pharmacol. 2006 Nov;57 Suppl 5:41-50
8890079 - J Pediatr Gastroenterol Nutr. 1996 Oct;23 (3):280-6
12395907 - Dig Dis Sci. 2002 Oct;47(10):2336-48
8871448 - Aliment Pharmacol Ther. 1996 Feb;10(1):91-5
19889500 - Pain. 2010 Jan;148(1):49-58
20518856 - Neurogastroenterol Motil. 2010 Sep;22(9):1029-35, e268
6880820 - Acta Psychiatr Scand. 1983 Jun;67(6):361-70
15743003 - Scand J Gastroenterol. 2004 Dec;39(12):1250-8
17013448 - J Gastrointestin Liver Dis. 2006 Sep;15(3):237-41
16268966 - Aliment Pharmacol Ther. 2005 Nov 15;22(10):927-34
20090435 - Clin J Pain. 2010 Feb;26(2):104-9
9777836 - Lancet. 1998 Oct 10;352(9135):1187-9
11899099 - Curr Top Med Chem. 2002 Feb;2(2):167-79
15479679 - Gut. 2004 Nov;53(11):1595-601
15747442 - FEMS Immunol Med Microbiol. 2005 Feb 1;43(2):213-22
2453678 - J Toxicol Environ Health. 1988;24(1):27-39
16185307 - Neurogastroenterol Motil. 2005 Oct;17(5):687-96
15128362 - Am J Gastroenterol. 2004 May;99(5):924-31
2679285 - Ann Intern Med. 1989 Oct 15;111(8):671-4
16846694 - Pain. 2006 Dec 15;126(1-3):79-90
15168372 - Gastroenterology. 2004 May;126(6):1620-33
11314746 - J Endocrinol Invest. 2001 Mar;24(3):173-7
2748771 - Psychiatry Res. 1989 May;28(2):193-213
15914575 - Gut. 2005 Oct;54(10):1402-7
15765388 - Gastroenterology. 2005 Mar;128(3):541-51
9143000 - Neuroendocrinology. 1997 Apr;65(4):284-90
20679498 - J Biol Rhythms. 2010 Aug;25(4):288-96
7605430 - BMJ. 1995 Jan 21;310(6973):171-5
19004650 - Eur J Pain. 2009 Sep;13(8):836-42
17659729 - World J Gastroenterol. 2007 Jul 21;13(27):3699-704
9146781 - Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
12482731 - Curr Opin Pharmacol. 2002 Dec;2(6):684-90
15667495 - Am J Gastroenterol. 2005 Feb;100(2):373-82
19996484 - J Physiol Pharmacol. 2009 Oct;60 Suppl 3:67-70
References_xml – volume: 15
  start-page: 237
  year: 2006
  end-page: 241
  ident: CR17
  article-title: Rome III: new standard for functional gastrointestinal disorders
  publication-title: J Gastrointestin Liver Dis
– volume: 28
  start-page: 193
  year: 1989
  end-page: 213
  ident: CR19
  article-title: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
  publication-title: Psychiatry Res
  doi: 10.1016/0165-1781(89)90047-4
– volume: 100
  start-page: 373
  year: 2005
  end-page: 382
  ident: CR4
  article-title: Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.40312.x
– volume: 38
  start-page: 503
  year: 2003
  end-page: 510
  ident: CR11
  article-title: Psychological factors in irritable bowel syndrome: a population-based study of patients, non-patients and controls
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520310002166
– volume: 53
  start-page: 1595
  year: 2004
  end-page: 1601
  ident: CR26
  article-title: Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls
  publication-title: Gut
  doi: 10.1136/gut.2003.028514
– volume: 13
  start-page: 836
  year: 2009
  end-page: 842
  ident: CR30
  article-title: Activating endogenous visceral pain modulation: a comparison of heterotopic stimulation methods in healthy controls
  publication-title: Eur J Pain
  doi: 10.1016/j.ejpain.2008.09.015
– volume: 10
  start-page: 91
  year: 1996
  end-page: 95
  ident: CR33
  article-title: Symptomatology, quality of life and economic features of irritable bowel syndrome–the effect of hypnotherapy
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.1996.tb00181.x
– ident: CR2
– volume: 65
  start-page: 284
  year: 1997
  end-page: 290
  ident: CR13
  article-title: Corticotropin-releasing hormone inhibits melatonin secretion in healthy volunteers—a potential link to low-melatonin syndrome in depression?
  publication-title: Neuroendocrinology
  doi: 10.1159/000127186
– volume: 126
  start-page: 79
  year: 2006
  end-page: 90
  ident: CR22
  article-title: Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls
  publication-title: Pain
  doi: 10.1016/j.pain.2006.06.017
– volume: 352
  start-page: 1187
  year: 1998
  end-page: 1189
  ident: CR7
  article-title: Abnormal colonic fermentation in irritable bowel syndrome
  publication-title: Lancet
  doi: 10.1016/S0140-6736(98)02146-1
– volume: 39
  start-page: 1250
  year: 2004
  end-page: 1258
  ident: CR9
  article-title: Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520410007953
– volume: 23
  start-page: 280
  year: 1996
  end-page: 286
  ident: CR8
  article-title: Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation
  publication-title: J Pediatr Gastroenterol Nutr
  doi: 10.1097/00005176-199610000-00013
– volume: 2
  start-page: 167
  year: 2002
  end-page: 179
  ident: CR31
  article-title: Melatonin-immune system relationships
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026023394335
– volume: 57
  start-page: 41
  year: 2006
  end-page: 50
  ident: CR32
  article-title: Nocturnal secretion of melatonin in patients with upper digestive tract disorders
  publication-title: J Physiol Pharmacol
– volume: 11
  start-page: 395
  year: 1997
  end-page: 402
  ident: CR23
  article-title: The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress
  publication-title: Aliment Pharmacol Ther
  doi: 10.1046/j.1365-2036.1997.142318000.x
– volume: 22
  start-page: 927
  year: 2005
  end-page: 934
  ident: CR15
  article-title: Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2005.02673.x
– volume: 111
  start-page: 671
  year: 1989
  end-page: 674
  ident: CR18
  article-title: A patient questionnaire to identify bowel disease
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-111-8-671
– volume: 24
  start-page: 27
  year: 1988
  end-page: 39
  ident: CR24
  article-title: Functional and biochemical effects on rat lung following instillation of crocidolite and chrysotile asbestos
  publication-title: J Toxicol Environ Health
  doi: 10.1080/15287398809531139
– volume: 43
  start-page: 213
  year: 2005
  end-page: 222
  ident: CR3
  article-title: Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome–a longitudinal study in IBS and control subjects
  publication-title: FEMS Immunol Med Microbiol
  doi: 10.1016/j.femsim.2004.08.009
– volume: 47
  start-page: 2336
  year: 2002
  end-page: 2348
  ident: CR16
  article-title: Gastrointestinal melatonin: localization, function, and clinical relevance
  publication-title: Dig Dis Sci
  doi: 10.1023/A:1020107915919
– volume: 310
  start-page: 171
  year: 1995
  end-page: 175
  ident: CR1
  article-title: Irritable bowel, irritable body, or irritable brain?
  publication-title: BMJ
  doi: 10.1136/bmj.310.6973.171
– volume: 126
  start-page: 1620
  year: 2004
  end-page: 1633
  ident: CR10
  article-title: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.03.024
– volume: 67
  start-page: 361
  year: 1983
  end-page: 370
  ident: CR20
  article-title: The hospital anxiety and depression scale
  publication-title: Acta Psychiatr Scand
  doi: 10.1111/j.1600-0447.1983.tb09716.x
– volume: 17
  start-page: 687
  year: 2005
  end-page: 696
  ident: CR5
  article-title: A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating
  publication-title: Neurogastroenterol Motil
  doi: 10.1111/j.1365-2982.2005.00695.x
– volume: 13
  start-page: 3699
  year: 2007
  end-page: 3704
  ident: CR27
  article-title: Abnormal endogenous pain modulation and somatic and visceral hypersensitivity in female patients with irritable bowel syndrome
  publication-title: World J Gastroenterol
– volume: 148
  start-page: 49
  year: 2010
  end-page: 58
  ident: CR29
  article-title: Widespread hypersensitivity is related to altered pain inhibition processes in irritable bowel syndrome
  publication-title: Pain
  doi: 10.1016/j.pain.2009.10.005
– volume: 60
  start-page: 67
  year: 2009
  end-page: 70
  ident: CR34
  article-title: Is melatonin involved in the irritable bowel syndrome?
  publication-title: J Physiol Pharmacol
– volume: 24
  start-page: 173
  year: 2001
  end-page: 177
  ident: CR12
  article-title: Actual stress, psychopathology and salivary cortisol levels in the irritable bowel syndrome (IBS)
  publication-title: J Endocrinol Invest
  doi: 10.1007/BF03343838
– volume: 22
  start-page: e268
  year: 2010
  ident: CR25
  article-title: The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat
  publication-title: Neurogastroenterol Motil
  doi: 10.1111/j.1365-2982.2010.01520.x
– volume: 54
  start-page: 1402
  year: 2005
  end-page: 1407
  ident: CR14
  article-title: Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study
  publication-title: Gut
  doi: 10.1136/gut.2004.062034
– volume: 2
  start-page: 684
  year: 2002
  end-page: 690
  ident: CR21
  article-title: Drugs targeting functional bowel disorders: lessons from drug trials
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/S1471-4892(02)00224-2
– volume: 25
  start-page: 288
  year: 2010
  end-page: 296
  ident: CR35
  article-title: Sex differences in phase angle of entrainment and melatonin amplitude in humans
  publication-title: J Biol Rhythms
  doi: 10.1177/0748730410374943
– volume: 26
  start-page: 104
  year: 2010
  end-page: 109
  ident: CR28
  article-title: Central processing of noxious somatic stimuli in patients with irritable bowel syndrome compared with healthy controls
  publication-title: Clin J Pain
  doi: 10.1097/AJP.0b013e3181bff800
– volume: 128
  start-page: 541
  year: 2005
  end-page: 551
  ident: CR6
  article-title: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.11.050
– volume: 38
  start-page: 503
  year: 2003
  ident: 3299_CR11
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520310002166
– volume: 24
  start-page: 173
  year: 2001
  ident: 3299_CR12
  publication-title: J Endocrinol Invest
  doi: 10.1007/BF03343838
– volume: 2
  start-page: 684
  year: 2002
  ident: 3299_CR21
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/S1471-4892(02)00224-2
– volume: 26
  start-page: 104
  year: 2010
  ident: 3299_CR28
  publication-title: Clin J Pain
  doi: 10.1097/AJP.0b013e3181bff800
– volume: 47
  start-page: 2336
  year: 2002
  ident: 3299_CR16
  publication-title: Dig Dis Sci
  doi: 10.1023/A:1020107915919
– volume: 54
  start-page: 1402
  year: 2005
  ident: 3299_CR14
  publication-title: Gut
  doi: 10.1136/gut.2004.062034
– volume: 67
  start-page: 361
  year: 1983
  ident: 3299_CR20
  publication-title: Acta Psychiatr Scand
  doi: 10.1111/j.1600-0447.1983.tb09716.x
– volume: 13
  start-page: 3699
  year: 2007
  ident: 3299_CR27
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v13.i27.3699
– volume: 43
  start-page: 213
  year: 2005
  ident: 3299_CR3
  publication-title: FEMS Immunol Med Microbiol
  doi: 10.1016/j.femsim.2004.08.009
– volume: 23
  start-page: 280
  year: 1996
  ident: 3299_CR8
  publication-title: J Pediatr Gastroenterol Nutr
  doi: 10.1097/00005176-199610000-00013
– volume: 65
  start-page: 284
  year: 1997
  ident: 3299_CR13
  publication-title: Neuroendocrinology
  doi: 10.1159/000127186
– volume: 15
  start-page: 237
  year: 2006
  ident: 3299_CR17
  publication-title: J Gastrointestin Liver Dis
– volume: 17
  start-page: 687
  year: 2005
  ident: 3299_CR5
  publication-title: Neurogastroenterol Motil
  doi: 10.1111/j.1365-2982.2005.00695.x
– volume: 126
  start-page: 1620
  year: 2004
  ident: 3299_CR10
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.03.024
– volume: 128
  start-page: 541
  year: 2005
  ident: 3299_CR6
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.11.050
– volume: 39
  start-page: 1250
  year: 2004
  ident: 3299_CR9
  publication-title: Scand J Gastroenterol
  doi: 10.1080/00365520410007953
– volume: 22
  start-page: e268
  year: 2010
  ident: 3299_CR25
  publication-title: Neurogastroenterol Motil
  doi: 10.1111/j.1365-2982.2010.01520.x
– volume: 13
  start-page: 836
  year: 2009
  ident: 3299_CR30
  publication-title: Eur J Pain
  doi: 10.1016/j.ejpain.2008.09.015
– volume: 126
  start-page: 79
  year: 2006
  ident: 3299_CR22
  publication-title: Pain
  doi: 10.1016/j.pain.2006.06.017
– volume: 148
  start-page: 49
  year: 2010
  ident: 3299_CR29
  publication-title: Pain
  doi: 10.1016/j.pain.2009.10.005
– volume: 310
  start-page: 171
  year: 1995
  ident: 3299_CR1
  publication-title: BMJ
  doi: 10.1136/bmj.310.6973.171
– volume: 25
  start-page: 288
  year: 2010
  ident: 3299_CR35
  publication-title: J Biol Rhythms
  doi: 10.1177/0748730410374943
– volume: 2
  start-page: 167
  year: 2002
  ident: 3299_CR31
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026023394335
– volume: 22
  start-page: 927
  year: 2005
  ident: 3299_CR15
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2005.02673.x
– volume: 28
  start-page: 193
  year: 1989
  ident: 3299_CR19
  publication-title: Psychiatry Res
  doi: 10.1016/0165-1781(89)90047-4
– volume: 11
  start-page: 395
  year: 1997
  ident: 3299_CR23
  publication-title: Aliment Pharmacol Ther
  doi: 10.1046/j.1365-2036.1997.142318000.x
– volume: 53
  start-page: 1595
  year: 2004
  ident: 3299_CR26
  publication-title: Gut
  doi: 10.1136/gut.2003.028514
– volume: 10
  start-page: 91
  year: 1996
  ident: 3299_CR33
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.1996.tb00181.x
– volume: 100
  start-page: 373
  year: 2005
  ident: 3299_CR4
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.40312.x
– volume: 111
  start-page: 671
  year: 1989
  ident: 3299_CR18
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-111-8-671
– volume: 24
  start-page: 27
  year: 1988
  ident: 3299_CR24
  publication-title: J Toxicol Environ Health
  doi: 10.1080/15287398809531139
– volume: 57
  start-page: 41
  year: 2006
  ident: 3299_CR32
  publication-title: J Physiol Pharmacol
– volume: 60
  start-page: 67
  year: 2009
  ident: 3299_CR34
  publication-title: J Physiol Pharmacol
– volume: 352
  start-page: 1187
  year: 1998
  ident: 3299_CR7
  publication-title: Lancet
  doi: 10.1016/S0140-6736(98)02146-1
– ident: 3299_CR2
  doi: 10.1111/j.1572-0241.2004.04161.x
– reference: 9146781 - Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
– reference: 12395907 - Dig Dis Sci. 2002 Oct;47(10):2336-48
– reference: 2679285 - Ann Intern Med. 1989 Oct 15;111(8):671-4
– reference: 19996484 - J Physiol Pharmacol. 2009 Oct;60 Suppl 3:67-70
– reference: 19004650 - Eur J Pain. 2009 Sep;13(8):836-42
– reference: 17659729 - World J Gastroenterol. 2007 Jul 21;13(27):3699-704
– reference: 15747442 - FEMS Immunol Med Microbiol. 2005 Feb 1;43(2):213-22
– reference: 11899099 - Curr Top Med Chem. 2002 Feb;2(2):167-79
– reference: 15479679 - Gut. 2004 Nov;53(11):1595-601
– reference: 15765388 - Gastroenterology. 2005 Mar;128(3):541-51
– reference: 20090435 - Clin J Pain. 2010 Feb;26(2):104-9
– reference: 12482731 - Curr Opin Pharmacol. 2002 Dec;2(6):684-90
– reference: 2748771 - Psychiatry Res. 1989 May;28(2):193-213
– reference: 16846694 - Pain. 2006 Dec 15;126(1-3):79-90
– reference: 17218759 - J Physiol Pharmacol. 2006 Nov;57 Suppl 5:41-50
– reference: 2453678 - J Toxicol Environ Health. 1988;24(1):27-39
– reference: 8871448 - Aliment Pharmacol Ther. 1996 Feb;10(1):91-5
– reference: 15128362 - Am J Gastroenterol. 2004 May;99(5):924-31
– reference: 9143000 - Neuroendocrinology. 1997 Apr;65(4):284-90
– reference: 19889500 - Pain. 2010 Jan;148(1):49-58
– reference: 17013448 - J Gastrointestin Liver Dis. 2006 Sep;15(3):237-41
– reference: 15667495 - Am J Gastroenterol. 2005 Feb;100(2):373-82
– reference: 20518856 - Neurogastroenterol Motil. 2010 Sep;22(9):1029-35, e268
– reference: 28443770 - Scand J Gastroenterol. 2003;38(5):503-510
– reference: 8890079 - J Pediatr Gastroenterol Nutr. 1996 Oct;23 (3):280-6
– reference: 16185307 - Neurogastroenterol Motil. 2005 Oct;17(5):687-96
– reference: 16268966 - Aliment Pharmacol Ther. 2005 Nov 15;22(10):927-34
– reference: 15914575 - Gut. 2005 Oct;54(10):1402-7
– reference: 15743003 - Scand J Gastroenterol. 2004 Dec;39(12):1250-8
– reference: 20679498 - J Biol Rhythms. 2010 Aug;25(4):288-96
– reference: 6880820 - Acta Psychiatr Scand. 1983 Jun;67(6):361-70
– reference: 7605430 - BMJ. 1995 Jan 21;310(6973):171-5
– reference: 11314746 - J Endocrinol Invest. 2001 Mar;24(3):173-7
– reference: 9777836 - Lancet. 1998 Oct 10;352(9135):1187-9
– reference: 15168372 - Gastroenterology. 2004 May;126(6):1620-33
SSID ssj0009716
Score 2.4004734
Snippet Background Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of...
Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of melatonin...
Background Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of...
Background: Probiotics have treatment efficacy in irritable bowel syndrome (IBS), but the exact mechanism remains obscure. One hypothesis is the mediation of...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 186
SubjectTerms Adult
Aged
Biochemistry
Care and treatment
Double-Blind Method
Female
Gastroenterology
Gastrointestinal diseases
Hepatology
Humans
Irritable bowel syndrome
Irritable Bowel Syndrome - physiopathology
Irritable Bowel Syndrome - therapy
Laws, regulations and rules
Male
Mediation
Medicine
Medicine & Public Health
Melatonin
Melatonin - biosynthesis
Melatonin - physiology
Middle Aged
Oncology
Original Article
Pain
Probiotics - chemistry
Probiotics - therapeutic use
Rectum - physiopathology
Saliva - chemistry
Sensory Thresholds
Sleep - physiology
Transplant Surgery
Treatment Outcome
Young Adult
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9RAEB9qC-IX8W20yoqCL5ZeNsluIojcSUsV7ziuVvot7GV2oXBNau-K6H_gf-1MHne9gvc5s2GTeexv5wnwSqVh5LVW0pP5l4SIncw0N3JF00PrjPH1tIbhSB8ex19PkpMtGHW1MJxW2dnE2lBjVbCPfC_kiswoJYH7dP5T8tQojq52IzRsO1oBP9Ytxm7ADpnklOR-Z7A_Gk9WbXhNPQyVcE4k6eqjuzhnU0ynFSdpxTIiGy3TtZPqur2-cmBdi6DWB9PBHbjdIkrRb0TgLmy58h7cHLYx8_vwd8j5bux1FZNm8DyxQti5sGJcsUbMnBg6LgA-nZ8JwrBiXPdmoteJNz-Ovr2M3gpa--WC3QhMPKh-uZk4alsdfBB9MbElVmenfxwKAuREIwczbsOIYsxe-mklOF3x9wM4Ptj__vlQtgMYZJHEaiGNwpAOUeNTjwbTLEaTkWXFwhGs0z0fotdOZ-htaFzGZdhK2ciraYYuSej6-xC2y6p0j0GgNhwoRsTUxlYlU4820zZWaCwhNh9Ar_vZedF2J-chGbN81VeZ-ZMTf3LmT54G8G655LxpzbGJ-DVzMGe1pfcWtq0-oN1xA6y8bwj4EDQMewHsrlGSuhXrjzsZyFt1n-cr4QzgxfIxr-QUttJVlzVNRD8vSvUmmiSm-yShqAAeNfK1_DTCqhlHjQN43wnclQ3877ufbN7uU7hFCDBpfEq7sL24uHTPCGUtps9b1fkHPqYfpQ
  priority: 102
  providerName: ProQuest
Title Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study
URI https://link.springer.com/article/10.1007/s10620-014-3299-8
https://www.ncbi.nlm.nih.gov/pubmed/25092036
https://www.proquest.com/docview/1642138048
https://www.proquest.com/docview/1643146386
https://www.proquest.com/docview/1654666381
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-xTUK8IL4JjMoIJL5kqXESO-EtRR3jo1PVUVSeLDe2pUldgtZOCP4D_mvu8tG1E0ziKQ85W4nPPv_su_sdwHORhpGXUnCP5p8jInY8k0TkalXfGqeUr6s1jI7k4TT-OEtmbR73sot271yStaXeSHaTgoKoYh6hDeXpDuwleHSneg1TkV8w7aq63ilCmYjj6UZ2rsy_dbG1GV02yRt70iUnab33HNyCmy1oZHmj5dtwzZV34PqodYvfhd8jCmmji1U2aWrL42gzs2SGjSua9AvHRo5yfE-WpwxhKhvX9EvYHXv59fjzs-gVw7YfzuimgIQH1Q-3YMctm8FblrOJKW11evLLWYaYG2X4YEFMi5aN6SJ-XjGKSPx5D6YHwy_vDnlbY4EXSSxWXAkb4j6pfOqtsmkWW5Wh8bSFQ-Qm-z60XjqZWW9C5TLKtBbCRF7MM-uSBE-492G3rEr3EJiVinzB1trUxEYkc29NJk0srDIIynwA_W6wddESkFMdjIW-oE4m_WjUjyb96DSA1-sm3xv2jauEX5AGNa1M7LcwbYIBfh1xXOlcIbZB9Bf2A9jfksQVVWy_7uaAblf0UoeUERylaPACeLp-TS0pSq101XktE-HgRam8SiaJ8ciIQCmAB838Wv8awtGMHMMBvOkm3MYH_Ou_H_2X9GO4gZgvaW6R9mF3dXbuniCuWs17sKNmqgd7-ftvn4b4HAyPxpNevbr-AF5sGbM
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwED-NTgJeEP8JDDACBANFNE5iJ0gTamFTy9qq6ja0t-DGtjSpS8baaRrfgC_FZ-Muf9p1En3bc86WnfPd_c7nuwN4wyPPt0Jw16L6dxERGzcWVMhVy6ZWRkpbdGvoD0TnIPh-GB6uwd86F4aeVdY6sVDUOk_pjvyTRxmZfoQH7svJL5e6RlF0tW6hoarWCnqrKDFWJXbsmotzdOGmW91vyO-3nO9s73_tuFWXATcNAz5zJdceWgppI6uljuJAyxjVh04NYhfRtJ62wohYW-VJE1OuMefKt3wcaxOG6OPhvDdgHWFHHDRgvb09GI4WZX9l0XwVcZXvoqsl6rhqmbwnOD0KC1wfbYIbLVnGq_bhkoG8ErEtDOHOXbhTIVjWKo_cPVgz2X242a9i9A_gT5_e19EtLxuVje6R9UxNmWLDnCRwYljfUMLx0fSYIWZmw6IWFE7H3v_Y6732NxmO7Z7StQURt_NzM2F7VWmFz6zFRirT-fHRb6MZOgBI47YnVPZRsyFFBcY5o-eRFw_h4FpY8QgaWZ6ZJ8C0kBSY1lpHKlA8HFutYqECrqVCVlkHmvXPTtKqGjo15ZgkizrOxJ8E-ZMQf5LIgQ_zISdlKZBVxO-IgwmpCZw3VVW2A66OCm4lLYlAC6Go13RgY4kSxTtd_lyfgaRSL9NkIQwOvJp_ppH0ZC4z-VlB4-PP8yOxiiYM0H9F1ObA4_J8zbeG2DimKLUDH-sDd2kB_9v309XLfQm3Ovv9XtLrDnafwW1En2F5n7UBjdnpmXmOCG82flGJEYOf1y25_wCmt1z_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGJk18QbwTGGAEiDdZNE5iJ0gTatmqla1V1G1o34Ib29KkLhlrp2n8A_4av4q7xGnXSfTbPuds2Tnf3WPfGyFveOwHVgjOLKh_BojYsERgIVctW1oZKW3VraE_EDuH4fej6GiF_G1yYTCsstGJlaLWZY5v5J99zMgMYiwza11YRLrV_Xr6i2EHKfS0Nu00lGuzoDercmMuyWPXXF7AdW6y2dsC3r_lvLt98G2HuY4DLI9CPmWSax-shrSx1VLHSahlAqpE5wZwjGhZX1thRKKt8qVJMO-YcxVYPkq0iSK478G8t8iaBCsJMrfW2R6kw3kJYFk1YgWMFTC4donGx1on8gmOAWIhC8A-sHjBSl63FVeM5TXvbWUUu3fJHYdmabs-fvfIiinuk_W-89c_IH_6GGuHL750WDe9h2NA1YQqmpYojWND-waTj48nJxTwM02rulAwHX3_Y3_vdfCBwtjeGT5hIHGnvDBjuu_KLHyhbTpUhS5Pjn8bTeEyADSsM8YSkJqm6CEYlRRDJS8fksMbYcUjslqUhXlCqBYSndRa61iFikcjq1UiVMi1VIAWrUdazc_OclcZHRt0jLN5TWfkTwb8yZA_WeyRj7Mhp3VZkGXE75CDGaoMmDdXLvMBVofFt7K2BNAFsNRveWRjgRJEPV_83JyBzKmaSTYXDI-8mn3GkRg-V5jyvKIJ4OcFsVhGE4VwlwUE55HH9fmabQ1wcoIea498ag7clQX8b99Ply_3JVkHCc72eoPdZ-Q2ANGoftraIKvTs3PzHMDedPTCSRElP29acP8BHiphKw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Melatonin+regulation+as+a+possible+mechanism+for+probiotic+%28VSL%233%29+in+irritable+bowel+syndrome%3A+a+randomized+double-blinded+placebo+study&rft.jtitle=Digestive+diseases+and+sciences&rft.au=Wong%2C+Reuben+K&rft.au=Yang%2C+Cao&rft.au=Song%2C+Guang-Hui&rft.au=Wong%2C+Jennie&rft.date=2015-01-01&rft.eissn=1573-2568&rft.volume=60&rft.issue=1&rft.spage=186&rft_id=info:doi/10.1007%2Fs10620-014-3299-8&rft_id=info%3Apmid%2F25092036&rft.externalDocID=25092036
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-2116&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-2116&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-2116&client=summon